Results 21 to 30 of about 5,926 (192)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107 [PDF]

Molecular Oncology
Advanced urothelial carcinoma (UC) requires new therapeutics beyond chemo‐ and immunotherapies. Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin‐treated UC, yielded limited response.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
doaj   +2 more sources

The Role of Oncology Nurses and Advanced Practice Providers in the Treatment of Patients With HRR-Deficient mCRPC Receiving Talazoparib Plus Enzalutamide: A Podcast [PDF]

Oncology and Therapy
Homologous recombination repair (HRR) is a DNA repair pathway that helps maintain genomic stability. About one quarter of patients with metastatic castration-resistant prostate cancer (mCRPC) have alterations in HRR genes.
Jennifer L. E. Lloyd, Julia Batten
doaj   +2 more sources

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry [PDF]

npj Breast Cancer
Germline BRCA1 and BRCA2 mutations enable targeted therapies in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The two poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib were ...
Manuel Hörner, Andreas Hartkopf, Nelson John, Philipp Ziegler, Lothar Häberle, Sabrina Uhrig, Chloë Goossens, Niklas Amann, Jan-Philipp Cieslik, Lara M. Tretschock, Dominik Dannehl, Thomas M. Deutsch, Moritz Dimpfl, Max Ehlert, Kathleen Eichstädt, Alexander Englisch, Melitta B. Köpke, Annika Krückel, Theresa Link, Annika Müller, Kristin Reinhardt, Jonas Roth, Henning Schäffler, Lea Sych, Nikolas Tauber, Christian M. Tegeler, Catharina Wichmann, Maggie Banys-Paluchowski, Henriette Princk, Achim Rody, Sara Y. Brucker, Nina Ditsch, Johannes Ettl, Tanja Fehm, Carolin C. Hack, Peyman Hadji, Alexander Hein, Wolfgang W. Janni, Hans-Christian Kolberg, Diana Lüftner, Michael P. Lux, Volkmar Müller, Florin-Andrei Taran, Hans Tesch, Diethelm Wallwiener, Frederik Marmé, Stephan Seitz, Erik Belleville, Laura L. Michel, Markus Wallwiener, Peter A. Fasching, Andreas Schneeweiss, Christian Maurer   +52 more
doaj   +2 more sources

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model

Frontiers in Oncology, 2019
Talazoparib, a potent PARP inhibitor, induces synthetic lethality in BRCA-deficient cancers making it an attractive candidate for ovarian cancer treatment.
Paige Baldwin, Anders Öhman, Daniela M Dinulescu   +2 more
exaly   +3 more sources

Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program [PDF]

BMC Cancer
Introduction Talazoparib is a strong PARP inhibitor with significant catalytic inhibition as well as the ability to cause PARP entrapment at DNA damage sites. It is one of the recommended treatments for individuals with BRCA-mutant advanced breast cancer,
Mehmet Ali Nahit Sendur, Mutlu Hizal, Burcu Çakar, Oktay Halit Aktepe, Emrah Eraslan, Zafer Arık, İsmail Erturk, Sercan Aksoy, Semra Paydaş, Serkan Değirmencioğlu, Cihan Erol, Necla Demir, Gülcan Bulut, Naziye Ak, Metin Özkan, Alper Sevinç, Nuriye Özdemir, Umut Dişel, Deniz Tural, Mehmet Artaç, Hacı Mehmet Türk, Serkan Menekşe, Sema Sezgin Göksu, Fatih Köse, Cağlayan Geredeli, Meral Günaldı, Başak Oyan Uluç, Fatma Şen, Kerem Oruç, Ömer Fatih Ölmez, Abdullah Sakin, Umut Demirci, Dilek Erdem, Ferhat Ekinci, Nihat Ökten, Leyla Özer, Kerem Okutur, Atakan Demir, Nuri Karadurmuş, Muhammed Bülent Akıncı, Bülent Yalçın, Erhan Gökmen   +41 more
doaj   +2 more sources

Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method

Heliyon, 2023
A rapid, sensitive, and simple UHPLC-MS/MS method for the determination of the PARP inhibitor talazoparib in mouse plasma was developed and validated using [13C,2H4]-talazoparib as an internal standard (IS).
Zahra Talebi, Dominique A. Garrison, Eric D. Eisenmann, Kalindi Parmar, Geoffrey I. Shapiro, Michelle A. Rudek, Alex Sparreboom, Yan Jin   +7 more
doaj   +1 more source

MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer

Frontiers in Oncology, 2022
MUS81 is a critical endonuclease involved in heterodimer formation with Eme1/Mms4 and an important DNA damage repair regulatory molecule. Our previous study suggested that MUS81 was overexpressed and its high expression was positively correlated with ...
Tao Wang, Peng Zhang, Chengguo Li, Weizhen Liu, Qian Shen, Lei Yang, Gengchen Xie, Jie Bai, Ruidong Li, Kaixiong Tao, Yuping Yin   +10 more
doaj   +1 more source

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

Frontiers in Oncology, 2021
Triple negative tumors represent 15% of breast cancer and are characterized by the lack of estrogen receptors, progesterone receptor, and HER2 amplification or overexpression.
Giacomo Barchiesi, Michela Roberto, Monica Verrico, Patrizia Vici, Silverio Tomao, Federica Tomao, Federica Tomao   +6 more
doaj   +1 more source

DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [18F]Talazoparib and its In Vivo Evaluation as a PARP Radiotracer.

, 2021
PARP inhibitors are proven chemotherapeutics and serve as lead structures for the development of PARP-targeted in vivo imaging probes. Given the clinical potential of PARP imaging for the detection and stratification of various cancers, the development ...
Christian, Geibel, Sophie, Stotz, Gregory D., Bowden, Andreas, Maurer, Michael, Laemmerhofer, Bernd J., Pichler, Johannes, Kinzler   +6 more
core   +1 more source

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial [PDF]

, 2023
Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose) polymerase.
Zschäbitz, Stefanie, Laird, A. Douglas, Fizazi, K, Zohren, F, Shore, Neal D., Voog, E, Oldenburg, Jan, Healy, Cynthia G., Agarwal, N, Azad, AA, Dunshee, C, Healy, CG, Laird, AD, Dunshee, Curtis, Carles, Joan, Lin, Xun, Fay, AP, Zschäbitz, S, Fong, Peter C. C., Jones, RJ, Voog, Eric, Fay, Andre P., Joung, Jae Young, De Giorgi, U, Shore, ND, Azad, Arun A., Fong, PCC, Oldenburg, J, Carles, J, Agarwal, Neeraj, Fizazi, Karim, Ye, Dingwei, Matsubara, N, Zohren, Fabian, Jones, Robert J., Di Santo, N, Ye, D, Joung, JY, Di Santo, Nicola, Lin, X, De Giorgi, Ugo, Matsubara, Nobuaki   +41 more
core   +4 more sources